Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

VITRAC Therapeutics Initiated Global Clinical Development of VIC-1911, licensed from Taiho Pharmaceutical

Tuesday, June 30, 2020

VITRAC Therapeutics, LLC (VITRAC) initiated the global clinical development of VIC-1911, an oncology candidate formally known as TAS-119, which was licensed from Taiho Pharmaceutical Co., Ltd. (Taiho), a Japan-based oncology company. Two Phase-1 clinical studies have been conducted in the US and Europe by Taiho. VITRAC obtained an exclusive and global development and commercialization rights for TAS-119, and its IND has been successfully transferred to VITRAC in the US with a new code name, VIC-1911.

“It is our honor to succeed the development of this drug that has been diligently developed by Taiho, and to be able to develop a potent Aurora A specific inhibitor, VIC-1911. This drug will give more treatment options to cancer patients since Aurora Kinase plays key oncogenic roles related to their mitotic activity, promote cancer cell survival, and proliferation,” said Keizo Koya, Ph.D., President of VITRAC Therapeutics.

VITRAC also made an alliance with JS InnoMed Holdings (JSI) by sublicensing the China rights of VIC-1911 to accelerate the global development. “JSI is an amazing biopharmaceutical company filled with creative and distinguished scientists managed by a notable leader, Dr. Jintao Zhang. It is exciting to collaborate on a global scale towards the development of this drug with potential to ameliorate the lives of patients,” said Dr. Koya.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024